Because the MEF2 transcription factor family is regulated by HDACs, HDAC inhibitors have been explored as therapeutic options and were found to be effective against MEF2D-rearranged ALL in vivo [21]. This evidence concerns the gene HDAC9 and acute lymphoblastic leukemia.